Correlation Between DXC Technology and FibroGen
Can any of the company-specific risk be diversified away by investing in both DXC Technology and FibroGen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DXC Technology and FibroGen into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between DXC Technology and FibroGen, you can compare the effects of market volatilities on DXC Technology and FibroGen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DXC Technology with a short position of FibroGen. Check out your portfolio center. Please also check ongoing floating volatility patterns of DXC Technology and FibroGen.
Diversification Opportunities for DXC Technology and FibroGen
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between DXC and FibroGen is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding DXC Technology and FibroGen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on FibroGen and DXC Technology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DXC Technology are associated (or correlated) with FibroGen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of FibroGen has no effect on the direction of DXC Technology i.e., DXC Technology and FibroGen go up and down completely randomly.
Pair Corralation between DXC Technology and FibroGen
If you would invest 651.00 in FibroGen on October 20, 2024 and sell it today you would earn a total of 557.00 from holding FibroGen or generate 85.56% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
DXC Technology vs. FibroGen
Performance |
Timeline |
DXC Technology |
FibroGen |
DXC Technology and FibroGen Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with DXC Technology and FibroGen
The main advantage of trading using opposite DXC Technology and FibroGen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DXC Technology position performs unexpectedly, FibroGen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will offset losses from the drop in FibroGen's long position.DXC Technology vs. Grupo Hotelero Santa | DXC Technology vs. Grupo Sports World | DXC Technology vs. FibraHotel | DXC Technology vs. Deutsche Bank Aktiengesellschaft |
FibroGen vs. Capital One Financial | FibroGen vs. Verizon Communications | FibroGen vs. Lloyds Banking Group | FibroGen vs. Micron Technology |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Complementary Tools
Stocks Directory Find actively traded stocks across global markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |